These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31309328)

  • 1. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
    Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
    Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
    Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
    Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
    Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer.
    Harada T; Tsuji T; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujiwara H; Fujita T
    Ann Surg Oncol; 2022 Dec; 29(13):8131-8139. PubMed ID: 35978207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer.
    Nakashima Y; Saeki H; Hu Q; Tsuda Y; Zaitsu Y; Hisamatsu Y; Ando K; Kimura Y; Oki E; Mori M
    Ann Surg Oncol; 2020 Feb; 27(2):492-498. PubMed ID: 31549319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
    Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
    Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
    Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
    Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Lyon TD; Frank I; Takahashi N; Boorjian SA; Moynagh MR; Shah PH; Tarrell RF; Cheville JC; Viers BR; Tollefson MK
    Clin Genitourin Cancer; 2019 Jun; 17(3):216-222.e5. PubMed ID: 31060857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
    Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
    Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
    Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
    Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
    Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
    Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia/Muscle Mass is not a Prognostic Factor for Short- and Long-Term Outcome After Esophagectomy for Cancer.
    Grotenhuis BA; Shapiro J; van Adrichem S; de Vries M; Koek M; Wijnhoven BP; van Lanschot JJ
    World J Surg; 2016 Nov; 40(11):2698-2704. PubMed ID: 27272482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of skeletal muscle measurement by computed tomography in patients with esophageal cancer: changes in skeletal muscle mass due to neoadjuvant therapy and the effect on the prognosis.
    Yamamoto M; Ozawa S; Koyanagi K; Kazuno A; Ninomiya Y; Yatabe K; Higuchi T; Kanamori K; Tajima K
    Surg Today; 2023 Jun; 53(6):692-701. PubMed ID: 36763134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
    Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
    Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.